PRAME and neoplasm: Thirty TCR sequences were cloned into a retroviral vector, transferred into recipient T-cells by retroviral transduction, and analyzed for expression of the TCRs on the cell surface, as well as for antigen-specific recognition of PRAME-positive, HLA-A2-positive tumor cell lines.